Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

China's Leading CRO, Wuxi PharmaTech, Sees Relatively Smooth Sailing Ahead Following Tempest-marked Odyssey Of Global Crisis

This article was originally published in PharmAsia News

Executive Summary

BEIJING - As the globe's pharmaceutical giants moved more research operations to lower cost China, the country's leading contract research organization, Wuxi PharmaTech, posted a strong rebound in 2009 earnings after recording a massive loss the previous year

You may also be interested in...



Japanese Nuclear Crisis Triggers Panic Buying Of Food And Drugs In China, Along With Selling Of Chinese Life Science Stocks

BEIJING - Virtual aftershocks from the 9.0 magnitude earthquake that rocked Japan, followed by a tsunami and a nuclear power plant crisis, are still reverberating across China

Japanese Nuclear Crisis Triggers Panic Buying Of Food And Drugs In China, Along With Selling Of Chinese Life Science Stocks

BEIJING - Virtual aftershocks from the 9.0 magnitude earthquake that rocked Japan, followed by a tsunami and a nuclear power plant crisis, are still reverberating across China

China's Leading Medical Equipment Maker Succeeds - Where Others Stumble - In Merging With U.S. Competitor

BEIJING - China's leading developer of medical devices, Mindray Medical International, is emerging as the golden success story in terms of a Chinese enterprise taking over an American competitor in the life sciences arena, with a 15.8 percent jump in net revenues for 2009 to $634.2 million

UsernamePublicRestriction

Register

MT125529

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel